Botox-induced prostatic involution

Prostate

Volumn 37, Issue 1, 1998, Pages 44-50

  Doggweiler, Ragi ^a   Zermann, Dirk Henrik ^a   Ishigooka, Manabu ^a   Schmidt, Richard A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Apoptosis; Atrophy; Botulinum toxin type A; BPH; Denervation; Neural control

Indexed keywords

BOTULINUM TOXIN A; NEUROTOXIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATROPHY; CONTROLLED STUDY; DENERVATION; INVOLUTION; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE; RAT;

ANIMALS; APOPTOSIS; ATROPHY; BOTULINUM TOXIN TYPE A; DENERVATION; HUMANS; MALE; NEUROMUSCULAR AGENTS; PROSTATE; PROSTATIC DISEASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031880756     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980915)37:1<44::AID-PROS7>3.0.CO;2-8     Document Type: Article

References (30)

1. De Groat WC: Neuroanatomy and neurophysiology: Innervation of the lower urinary tract. In Raz S (ed): "Female Urology," Philadelphia: W.B. Saunders, 1996:28-42.
2. Schmidt RA: Urethrovesical reflexes and their inhibition. In Hinman F (ed): "Benign Prostatic Hypertrophy," New York: Springer-Verlag, 1983:361-372.
3. Wang JM, McKenna KE, McVary KT, Lee C: Requirement of innervation for maintenance of structural and functional integrity in the rat prostate. Biol Reprod 1991;44:1171-1176.
4. Chalfin SA, Bradley WE: The etiology of detrusor hyperreflexia in patients with intravesical obstruction. J Urol 1982;127:938-942.
5. Isaacs JT, Coffey DS: Etiology and disease process of benign prostate hyperplasia. Prostate [Suppl] 1989;2:33-50.
6. McConnell JD: Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990; 17:661-670.
7. Gleason PE, Jones JA, Regan JS, Salvas DB, Eble JN, Lamph WW, Vlahos CJ, Huang WL, Falcone JF, Hirsch KS: Platelet derived growth factor (PDGF), androgens and inflammation: Possible etiologic factors in the development of prostatic hyperplasia. J Urol 1993;149:1586-1592.
8. Roberts RO, Jacobsen SJ, Rhodes T, Guess HA, Girman CJ, Panser LA, Chute CG, Oesterling JE, Lieber MM: Cigarette smoking and prostatism: A biphasic association? Urology 1994; 43:797-801.
9. Chyou PH, Nomura AM, Stemmermann GN, Hankin JH: A prospective study of alcohol, diet, and other lifestyle factors in relation to obstructive uropathy. Prostate 1993;22:253-264.
10. Cockett AT, di Sant'Agnese PA, Gopinath P, Schoen SR, Abrahamsson PA: Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Urology 1993;42: 512-519.
11. Gkonos PJ, Krongrad A, Roos BA: Neuroendocrine peptides in the prostate. Urol Res 1995;23:81-87.
12. Davis LE: Botulinum toxin - From poison to medicine. West J Med 1993;158:25-29.
13. Jankovic J, Brin MF: Therapeutic uses of Botulinum toxin. N Engl J Med 1991;324:1186-1194.
14. Schantz EJ, Johnson EA: Properties and use of Botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56:80-99.
15. Pasricha PJ, Rai R, Ravich WJ, Hendrix TR, Kalloo AN: Botulinum toxin for achalasia: Long term outcome and predictors of response. Gastroenterology 1996;110:1410-1415.
16. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD: Effects of Botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;136:919-922.
17. Black JD, Dolly JO: Interaction of 1251-labeled Botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 1986;103: 521-534.
18. Black JD, Dolly JO: Interaction of 125I-labeled Botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 1986;103:535-544.
19. Linial M: Bacterial neurotoxins - Thousand years later. Isr J Med Sci 1995;31:591-595.
20. Harris CP, Alderson K, Nebeker J, Holds JB, Anderson RL: Histologic features of human orbicularis oculi treated with Botulinum A toxin. Arch Ophthalmol 1991;109:393-395.
21. Coffield JA, Considine RV, Simpson LL: The site and mechanism of action of Botulinum neurotoxin. In Jankovic, J Hallett M (eds): "Therapy With Botulinum Toxin," New York: Marcel Dekker, 1994:3-13.
22. MacKenzie I, Burnstock G, Dolly JO: The effects of purified Botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomi neuromuscular transmission. Neuroscience 1982;7:997-1006.
23. Martinez-Pineiro L, Dahita R, Nunes LL, Tanagho E, Schmidt RA: Pelvic plexus denervation in rats causes morphologic and functional changes of the prostate. J Urol 1993;150:215-218.
24. Blacklock NJ: The morphology of the parenchyma of the prostate. Urol Res 1977;5:155-158.
25. Aumueller G: Morphologic and endocrine aspects of prostatic function. Prostate 1983;4:195-214.
26. Bruschini H, Schmidt RA, Tanagho EA: Neurologic control of prostatic secretion in the dog. Invest Urol 1978;15:288-290.
27. Gschwend JE: Apoptosis principles and importance of programmed cell death for prostatic carcinoma. Urologe [A] 1996; 35:390-399.
28. Hellstrom WJG, Schmidt RA, Lue TF, Tanagho EA: Neuromuscular dysfunction in nonbacterial prostatitis. Urology 1987;30: 183-188.
29. Danuser H, Springer JP, Katofiasc MA, Thor KB: Extrinsic innervation of the cat prostate gland: A combined tracing and immunohistochemical study. J Urol 1997;157:1018-1024.
30. Clemow DB, McCarty R, Steers WD, Turtle JB: Efferent and afferent neuronal hypertrophy associated with micturition pathways in spontaneously hypertensive rats. Neurourol Urodyn 1997;16:293-303.